Citations

Clear

2 citation(s) found for "Stanton, Christopher".

Safety and efficacy of colchicine for the prevention of post-operative atrial fibrillation in patients undergoing cardiac surgery: a meta-analysis of randomized controlled trials
Agarwal, Siddharth , Beard, Christopher , Khosla, Jagjit , Clifton, Shari , Anwaar, Muhammad Faraz , Ghani, Asad , Farhat, Kassem , Pyrpyris, Nikolaos , Momani, J , Munir, Muhammad Bilal , Deshmukh, Abhishek , Stavrakis, Stavros , Jackman, Warren M. , Po, Sunny S. , Asad, Zain Ul Abideen , Beard, Christopher W , Momani, Joud , Deshmukh, Abhishek J , Stavrakis, Stavros , Po, Sunny , Asad, Zain Ul Abideen , Munir, Muhammad Bilal , Agarwal, Siddharth , DeSimone, Christopher V.

Mayo Clinic

Europace | June 22, 2023 | Volume: 25 | Issue: 7 | Pages: No page available

10.1093/europace/euad169 | PMID 37341446 Get It

Abstract Background and Aims Colchicine is an anti-inflammatory drug that may prevent post-operative atrial fibrillation (POAF). The effect of this drug has been inconsistently shown in previous clinical trials. We aimed to compare the efficacy and safety of colchicine vs. placebo to prevent POAF in patients undergoing cardiac surgery. Methods and results A systematic search of EMBASE, MEDLINE, SCOPUS, ClinicalTrials.gov, and the Cochrane Library for randomized controlled trials (RCTs) was conducted from inception till April 2023. The primary outcome was the incidence of POAF after any cardiac surgery. The secondary outcome was the rate of drug discontinuation due to adverse events and adverse gastrointestinal events. Risk ratios (RR) were reported using the Mantel Haenszel method. A total of eight RCTs comprising 1885 patients were included. There was a statistically significant lower risk of developing POAF with colchicine vs. placebo (RR: 0.70; 95% CI: 0.59–0.82; P < 0.01, I2 = 0%), and this effect persisted across different subgroups. There was a significantly higher risk of adverse gastrointestinal events (RR: 2.20; 95% CI: 1.38–3.51; P < 0.01, I2 = 55%) with no difference in the risk of drug discontinuation in patients receiving colchicine vs. placebo (RR: 1.33; 95% CI: 0.93–1.89; P = 0.11, I2 = 0%). Conclusion This meta-analysis of eight RCTs shows that colchicine is effective at preventing POAF, with a significantly higher risk of adverse gastrointestinal events but no difference in the rate of drug discontinuation. Future studies are required to define the optimal duration and dose of colchicine for the prevention of POAF.
Abstract 2700: Reduced Ejection Fraction is Associated with Poor Outcomes in Adults with Left Ventricular Noncompaction Syndrome
Stanton, Christopher, Brady, Peter A. , Hodge, David O. , Friedman, Paul A. , Asirvatham, Samuel J. , Bruce, Charles J.

Mayo Clinic

Circulation | July 3, 2021 | Volume: 116 | Issue: suppl_16 | Pages: No page available

10.1161/circ.116.suppl_16.ii_599 Get It

Introduction Left ventricular non-compaction (LVNC) is a rare cardiomyopathy thought to result from intrauterine arrest of myocardial compaction which has been associated with and increased risk of sudden cardiac death (SCD). However, appropriate identification of at-risk individuals and risk-stratification is lacking, particularly in patients diagnosed during adulthood. We sought to identify high-risk patients wtih LVNC in order to guide therapy. Hypothesis That patients with decreased left ventricular ejection fraction (LVEF) would have worse outcomes than those with preserved left ventricular function. Methods We reviewed outcomes in all patients diagnosed with LVNC at Mayo Clinic between 2001 through 2006. Data were prospectively entered into a centralized database and retrospectively analyzed. Mortality was compared to age and sex matched population rates. Results A total of 80 patients were diagnosed with LVNC during this interval. After exclusion of pediatric patients (n = 21), 59 adult patients (62% male; age 46 ± 19 years, range 18–83) were analyzed. There were 4 deaths in this group (none due to stroke, mortality 18% at 2 years) during follow-up (mean 13.0 ± 13.5 months, range 0–52). Overall survival of patients with LVNC was worse than age and sex matched controls (Minnesota population p < 0.001). This was also noted in patients with LVEF > 35% (n = 35, p = 0.02). Overall LVEF was 41 ± 16% but was lower in patients who died compared to survivors (26 ± 10% vs. 42 ± 15%; Hazard ratio = 2.0 for a decrease in ejection fraction of 10%, p = 0.12). There were no deaths in patients with LVEF > 50% (n = 17). Conclusion Survival of adults with LVNC is worse than expected for age and sex. A decrease in ejection fraction is associated with increased risk of death in this population. These data suggest that patients diagnosed with LVNC and reduced LVEF may benefit from ICD implantation, whereas patients with a normal LVEF may be observed.